
Every January, the healthcare industry squeezes into a few blocks of San Francisco for one week. Most emerging companies won't be on the main stage. They'll be in hotel suites, partnering systems and side events, trying to turn 30-minute meetings into a term sheet or a partnership.
Capital is flowing again, but to fewer companies with clearer milestones. J.P. Morgan's Q3 2026 biopharma report counts $7.5 billion raised across 22 biopharma IPOs through September, more than any full year from 2022 to 2025. Biopharma M&A reached $138.9 billion in upfront cash across 113 deals, already ahead of all of 2025. The XBI biotech index was up almost 30% through Q3, roughly double the Nasdaq.
Venture money is growing too ($23.9 billion through Q3, on pace for about $33 billion this year versus $30.5 billion in 2025), but it isn't spreading evenly:
In plain terms: investors are writing bigger checks to fewer companies, closer to clinical proof.
After JPM 2026, commentators described dealmaking as disciplined, with much of it running through licensing rather than headline mergers. Expect the same mood in 2027, with one difference: more companies now have a realistic shot at an IPO or acquisition, so more will compete for the same rooms.
1. Your value inflection point has to be obvious. When capital concentrates in later rounds, investors want to see exactly what their money buys: which data readout, by when, and why that milestone changes what the company is worth. If someone has to dig for that on slide 9, it's buried.
2. Pharma is shopping earlier, and globally. EY found that 63% of life sciences deals in the first half of 2026 targeted assets before Phase III, a record. At the same time, China-origin assets made up 51% of big pharma licensing deals with upfronts of $50 million or more this year, and 65% of the upfront dollars, according to J.P. Morgan. If you're meeting a BD team, assume they've already seen a faster or cheaper version of your mechanism. Your differentiation has to say why yours wins, in one sentence.
3. Two audiences, two stories. Many companies will pitch investors and partners in the same week, and the two ask different questions. Investors want the financing story: what this round gets you to, and why that matters for valuation. Partners want the asset story: differentiation, data, competitive position, and which rights are on the table. One deck rarely serves both.
JPM Week is expensive: partnering fees, hotel rates and travel add up fast. Go on purpose, not because everyone else does. It's usually worth it if:
If you're very early, with no data and no clear ask, one or two targeted side events, or the virtual partnering days that Biotech Showcase, RESI and QNova run after the week, may give you more value per dollar.
Several partnering events run alongside the main conference, no invitation needed:
Banks, law firms and regional groups host receptions all week, and many second meetings get set up there.
Space is the hard part. Meeting space near Union Square is scarce and expensive that week (in 2026, one venture firm rented a bus as a mobile meeting room). Decide early whether you'll use partnering tables, a shared suite or virtual calls, and budget for it.
This is where companies most often lose the room, so the best-prepared ones bring three versions of the same story. Before you fly, have:
In the room, skip the long introduction; the people across the table have done their homework. Investors sit through back-to-back meetings all week, and too much science can bury your value proposition. Your goal in 30 minutes isn't to share the whole book. It's to earn a follow-up meeting. Less is more.
Cooley's JPM readiness guide makes a point worth acting on: many attendees will use AI tools to research your company before a meeting. That matches the broader shift we covered in our State of AI in Marketing report, where Forrester found 89% of B2B buyers now use generative AI in their research. Investors and BD teams are no exception.
Your public footprint is part of your pitch now. Before December, check:
If the answer is vague or out of date, the cause is usually in your own materials: an old tagline, a stale team page, a description that doesn't match the deck. These are quick fixes worth making before anyone starts their homework on you.
JPM Week is biopharma's busiest news week. Large companies use it for guidance, deals and pipeline updates, and a small company's press release is easy to miss. Two windows work better:
Whatever you announce, update your website, deck and leadership LinkedIn profiles the same day so the story matches when people look you up. Then plan a few simple LinkedIn posts: one saying you'll be in San Francisco, a quick update during the week, and a thank-you after.
Once the meetings end, the receptions begin: dozens of evening events, some open to anyone who registers, many invitation-only. After a day of back-to-back partnering, don't say yes to everything. Pick the two or three events each night where your target list is most likely to be, and save energy for the next morning. On Your Mark keeps a free, searchable list of public and invite-only JPM Week 2027 events.
Follow up within 48 hours. As one investor told BioSpace, nobody closes an investment at JPM. The week sets up the conversations that do.
Log notes the same day, while you still remember who said what, and send whatever you promised. Momentum fades within about two weeks as everyone returns to internal reviews and full inboxes. End every meeting with a defined next step, such as a confidentiality agreement, a data request or a date for the next call, so the follow-up writes itself.
The capital is there in 2027. The patience is shorter. In a market this selective, the companies that come home with second meetings tend to be the ones whose story, materials and online presence all say the same clear thing before the first handshake.
Heading to JPM this year? Markeny helps life sciences companies sharpen investor and partner narratives, decks, and the digital footprint that gets checked before the meeting. Get in touch.
JPM Week runs January 11–15, 2027, in San Francisco. The invitation-only J.P. Morgan Healthcare Conference is January 11–14 at the Westin St. Francis.
In San Francisco's Union Square area. The main conference is at the Westin St. Francis; BIO Partnering and RESI JPM are at the San Francisco Marriott Marquis; Biotech Showcase and the QNova Partnering Forum are at the Hilton San Francisco Union Square; and ABD Capital Connect is at the Marines' Memorial Club.
No. Most emerging companies work the week through partnering events such as BIO Partnering @ JPM Week, Biotech Showcase, RESI JPM, the QNova Partnering Forum and ABD Capital Connect, plus their own meeting space and evening receptions.
Stronger but selective. Through Q3 2026, biopharma IPOs, M&A and venture funding were all ahead of 2025, according to J.P. Morgan. But about 72% of venture capital went to Series B and later rounds, and first-time financings slowed.
A paid partnering system run by BIO that lets registered companies and investors schedule in-person or virtual meetings during JPM Week, with meeting tables at the San Francisco Marriott Marquis. It is not affiliated with J.P. Morgan and does not give access to the main conference.
Start outreach in November and aim to lock meeting times around Thanksgiving. Calendars fill well before the holidays.
Usually not. Investors focus on the financing story and value inflection; partners focus on differentiation, data, competitive position and available rights.
It depends on your goals. It's usually worth it if you're raising in the next 6–12 months or partnering an asset. Very early companies with no data or clear ask may get more value from one or two targeted side events or virtual partnering days.
Usually the week before JPM or in late January. During JPM Week, large-company announcements dominate the headlines and smaller companies' news is easy to miss.
It can be, if you treat it as a way to get meetings. Presenting adds credibility, puts you on the list investors scan to request meetings, and gives you a recording to reuse in follow-ups. But presenting slots are usually paid, rooms can be thin while investors are in one-on-ones, and deals come from meetings, not the stage. It's most worth it if you're raising within six months, your story is sharp, and you invite your target investors to your slot.
J.P. Morgan (Q3 2026 Biopharma Licensing and Venture Report) · EY (H1 2026 life sciences deals report) · IQVIA (Biopharma M&A mid-year 2026 update) · BIO (BIO Partnering @ JPM Week) · Informa Connect (Biotech Showcase 2027) · Life Science Nation (RESI JPM 2027) · QNova LifeSciences and MTEC (Partnering Forum 2027) · American Business Development (ABD Capital Connect 2027) · Cooley (Making the Most of JPM) · BioSpace · Seed Healthcare and Mondaq (JPM 2026 takeaways) · Vision Life Sciences (JPM 2027 guide) · ABC7 News